Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults

At day 28 after the full vaccination, both the low-dose and the high-dose CS-2034 vaccine were able to induce the production of high titers of S-RBD IgG antibodies against the BA.1 strain. Adverse reactions in the low-dose and high-dose groups were mainly of severity grade 1 or 2, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.

Source: Journal of Infection - October 27, 2023 Category: Infectious Diseases Authors: Zhili Jin, Jingxuan Wu, Ying Wang, Tao Huang, Kexin Zhao, Jian Liu, Haomeng Wang, Tao Zhu, Jinbo Gou, Haitao Huang, Xiaofang Wu, Hang Yin, Jian Song, Ran Li, Jianxiong Zhang, Lijun Li, Jingcheng Chen, Xiao Li, Meijuan Zhang, JiangShuo Li, Mengyu Hou, Yuqi Source Type: research